retatrutide clinical trial information Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Eli Lilly infiltrates anti-obesity market

Studies have shown that these medications can reduce the risk of heart attacks, strokes, kidney disease, obstructive sleep apnea and now possibly cancer

Borner, T., De Jonghe, B

In the retatrutide Phase 2 trial, high-sensitivity CRP fell alongside body weight [1], which mechanistically predicts improved central androgen signaling even before peripheral hormone levels are measured

Gastaldelli A, Cusi K, Fernandez Lando L, Bray R, Brouwers B, Rodriguez A

The Phase 2 clinical trial, published in the New England Journal of Medicine, demonstrated remarkable outcomes

The speed and extent of weight loss with retatrutide are not uniform across all individuals